Bulletin
Investor Alert

New York Markets Open in:

×

press release

Aug. 21, 2019, 4:10 p.m. EDT

Arcus Biosciencesto Present at Upcoming Investor Conferences

Arcus Biosciences, Inc. /zigman2/quotes/205229230/composite RCUS -2.38% , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that the Company will participate in the following upcoming investor conferences:

  • Citi’s 14th Annual Biotech Conference on Wednesday, September 4, 2019, at 9:30 am Eastern Time in Boston. Terry Rosen, Ph.D., Chief Executive Officer, will participate in a panel discussion entitled, “New Targets in Cancer Immunotherapy and the Tumor Microenvironment.”

  • Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10, 2019, at 11:10 am Eastern Time in New York. Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat.

A live audio webcast of each presentation will be available by visiting the “Investors” section of the Arcus website at www.arcusbio.com . A replay of the webcasts will be available for 30 days following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies. Arcus has several programs targeting important oncology/immuno-oncology pathways, including a dual adenosine receptor antagonist, AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody, AB122, which is progressing into a Phase 1b trial in biomarker-selected patients. AB122 is expected to form the backbone for many of Arcus’s intra-portfolio combinations. Arcus’s other programs include AB154, an anti-TIGIT antibody, which is being evaluated in a Phase 1 trial as monotherapy and in combination with AB122, and AB680, a small-molecule inhibitor of CD73, which is progressing into a Phase 1/1b trial in patients with pancreatic cancer. Arcus has extensive in-house expertise in medicinal chemistry, oncology, immunology, biochemistry, pharmacology and structural biology. Utilizing these unique capabilities, Arcus has developed a robust and active early-stage discovery effort focused on small-molecule pipeline expansion. For more information about Arcus Biosciences, please visit www.arcusbio.com .

View source version on businesswire.com: https://www.businesswire.com/news/home/20190821005629/en/

SOURCE: Arcus Biosciences, Inc.

Katherine Bock
(510) 694-6231
kbock@arcusbio.com Nicole Arndt
(510) 284-4728
narndt@arcusbio.com

Copyright Business Wire 2019

/zigman2/quotes/205229230/composite
US : U.S.: NYSE
$ 9.03
-0.22 -2.38%
Volume: 222,211
Sept. 19, 2019 6:30p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$414.02 million
Rev. per Employee
$77,343
loading...

Comtex
Link to MarketWatch's Slice.